Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Interstitial Cystitis
Urigen Pharmaceuticals, Inc. Initiates URG101-104 Phase II Pharmacodynamic Clinical Trial for Painful Bladder Syndrome/Interstitial Cystitis
August 27th, 2007
Urigen Pharmaceuticals, Inc. (URGP.OB), a specialty pharmaceutical company focused on the development of treatments for urological disorders, has initiated a double-blind, placebo controlled, cross-over study to investigate URG-101 as a treatment for acute symptoms of painful bladder syndrome/interstitial cystitis (PBS). The URG101-104 study will compare the efficacy of URG101 (intravesical lidocaine-heparin formulation) and placebo in reducing acute symptoms of PBS. The study will enroll patients at several U.S. clinical sites with the first patient having been enrolled and dosed. "The URG101-104 study is important for those patients diagnosed with...
Source: Clinical Trials Week (2007-08-27)
|
